Author

K. Behbakht

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

B. G. Bitler· 4 shared M. J. Sikora· 3 shared A. Clauset· 2 shared J. K. Richer· 2 shared K. R. Jordan· 2 shared T. M. Yamamoto· 2 shared Z. L. Watson· 2 shared A. D. Jeong· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

B. G. Bitler

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma

L. B. Van Kleunen, M. Ahmadian, M. D. Post, R. J. Wolsky, C. Rickert, K. Jordan, J. Hu, J. K. Richer, N. A. Marjon, K. Behbakht, M. J. Sikora, B. G. Bitler, A. Clauset

The paper uses spatial data from ovarian cancer tumors to show that spatial organization of the immune microenvironment correlates with patient outcomes and can predict treatment response.

bioRxiv · Jan 26, 2024Cancer Biology

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models

L. L. Nguyen, Z. L. Watson, R. Ortega, E. R. Woodruff, K. R. Jordan, R. Iwanaga, T. M. Yamamoto, C. A. Bailey, A. D. Jeong, S. Guntupalli, K. Behbakht, V. Gibaja, N. Arnoult, E. Chuong, B. G. Bitler

bioRxiv · Feb 23, 2023 · PreprintCancer Biology

The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval

K. R. Jordan, M. J. Sikora, J. E. Slansky, A. Minic, J. K. Richer, M. R. Moroney, J. C. Costello, A. Clauset, K. Behbakht, T. R. Kumar, B. G. Bitler

This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.

Clinical Cancer Research · Dec 1, 2020Peer-reviewedCancer Biology

Targeting Wnt Signaling To Overcome PARP Inhibitor Resistance

T. M. Yamamoto, A. McMellen, Z. L. Watson, J. Aguilera, M. J. Sikora, R. Ferguson, E. Nurmemmedov, T. Thakar, M. George-Lucian, H. Kim, D. M. Cittelly, H. Wilson, K. Behbakht, B. G. Bitler

This study identifies Wnt signaling activation as a mechanism of PARP inhibitor resistance in HGSOC and shows that combining PARPi with Wnt inhibitors reduces tumor burden.

bioRxiv · Jul 27, 2018 · PreprintCancer Biology